Literature DB >> 1552037

General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research.

J G Rabkin1, J S Markowitz, K Ocepek-Welikson, S S Wager.   

Abstract

This study compares two methods for elicitation of treatment-emergent side effects. One is the open-ended general inquiry and the other is a specific inquiry that asks about a wide range of events thought to be treatment-related. The study goal was to determine the extent to which the specific inquiry method elicits clinically useful information over and above that elicited by the general inquiry method. The assessment instrument we used is SAFTEE, a structured interview schedule developed by the National Institute of Mental Health. We looked for differences between general and specific inquiry formats in terms of number of events elicited, type of event, severity, functional impairment, and clinician action taken. We found that both methods contributed to elicitation of events that, in the clinician's opinion, required some change in management. However, events reported on the General Inquiry form were significantly more distressing, more often interfered with daily functioning, and elicited more extensive changes in clinical management. No medically serious events were elicited on the specific inquiry form alone. Based on these findings, and in view of the amount of time and effort required to administer and score it, we do not recommend the specific inquiry form of SAFTEE as a standard assessment tool for routine use in all clinical trials. We do consider it to be a useful method for comprehensive elicitation about treatment-emergent effects in targeted and specific research contexts. We see the schedule as a comprehensive document or library of queries to be tailored to the needs of individual protocols.

Mesh:

Substances:

Year:  1992        PMID: 1552037     DOI: 10.1097/00001573-199202000-00002

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  14 in total

1.  Detecting treatment emergent adverse events in clinical trials : a comparison of spontaneously reported and solicited collection methods.

Authors:  Joachim F Wernicke; Douglas Faries; Denái Milton; Karen Weyrauch
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

2.  A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence.

Authors:  Helen M Pettinati; Kyle M Kampman; Kevin G Lynch; Hu Xie; Charles Dackis; Amanda R Rabinowitz; Charles P O'Brien
Journal:  Addict Behav       Date:  2007-11-17       Impact factor: 3.913

3.  A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder.

Authors:  David Mischoulon; Lawrence H Price; Linda L Carpenter; Audrey R Tyrka; George I Papakostas; Lee Baer; Christina M Dording; Alisabet J Clain; Kelley Durham; Rosemary Walker; Elizabeth Ludington; Maurizio Fava
Journal:  J Clin Psychiatry       Date:  2014-04       Impact factor: 4.384

4.  Treatment of late-life depression complicated by alcohol dependence.

Authors:  David W Oslin
Journal:  Am J Geriatr Psychiatry       Date:  2005-06       Impact factor: 4.105

5.  A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence.

Authors:  Helen M Pettinati; David W Oslin; Kyle M Kampman; William D Dundon; Hu Xie; Thea L Gallis; Charles A Dackis; Charles P O'Brien
Journal:  Am J Psychiatry       Date:  2010-03-15       Impact factor: 18.112

6.  A Randomized Controlled Trial of Medication and Cognitive-Behavioral Therapy for Hypochondriasis.

Authors:  Brian A Fallon; David K Ahern; Martina Pavlicova; Iordan Slavov; Natalia Skritskya; Arthur J Barsky
Journal:  Am J Psychiatry       Date:  2017-06-29       Impact factor: 18.112

7.  Dose increase of S-Adenosyl-Methionine and escitalopram in a randomized clinical trial for major depressive disorder.

Authors:  Hitoshi Sakurai; Linda L Carpenter; Audrey R Tyrka; Lawrence H Price; George I Papakostas; Christina M Dording; Albert S Yeung; Cristina Cusin; Elizabeth Ludington; Richard Bernard-Negron; Maurizio Fava; David Mischoulon
Journal:  J Affect Disord       Date:  2019-10-31       Impact factor: 4.839

8.  Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study.

Authors:  Judith G Rabkin; Martin C McElhiney; Richard Rabkin; Patrick J McGrath
Journal:  J Clin Psychiatry       Date:  2010-05-04       Impact factor: 4.384

9.  Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence.

Authors:  Helen M Pettinati; Kyle M Kampman; Kevin G Lynch; Jesse J Suh; Charles A Dackis; David W Oslin; Charles P O'Brien
Journal:  J Subst Abuse Treat       Date:  2007-07-30

10.  Varenicline augmentation in depressed smokers: an 8-week, open-label study.

Authors:  Noah S Philip; Linda L Carpenter; Audrey R Tyrka; Laura B Whiteley; Lawrence H Price
Journal:  J Clin Psychiatry       Date:  2009-03-24       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.